The Influence of Gene Polymorphism on Clinical Outcomes in Patients Undergoing PCI
Status
Conditions
Treatments
Details and patient eligibility
About
Dual antiplatelet therapy with aspirin and thienopyridines is an essential treatment in patients undergoing percutaneous coronary intervention (PCI). However, despite intensified antiplatelet treatment, some of the patients undergoing PCI develop thrombotic stent occlusion, suggesting incomplete platelet inhibition due to thienopyridine resistance. Some patients develop bleeding event because of the improper dosage and covariation. This observational study is designed for clarifying the Influence of gene polymorphism on clinical outcomes in patients undergoing PCI.
Full description
Patients undergoing PCI who received dual antiplatelet therapy with both aspirin (100mg) and P2Y12 inhibitors in standard dosage were enrolled. Investigators examined plasma biomarkers for platelet activation and DNA in those patients, and then analyzed the CYP2C19 genetic polymorphism to examine the influence of this genetic variation on the several biomarkers for platelet activation and bleeding event.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- The patients undergoing PCI
- More than 18 years old
- Treated with aspirin and P2Y12 inhibitors (clopidogrel or ticagrelor)
Exclusion criteria
Inability to provide written informed consent
Trial contacts and locations
Loading...
Central trial contact
Yujie Zhou, PhD,MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal